Nightly Home Hemodialysis Gains First FDA Clearance
This article was originally published in The Gray Sheet
Executive Summary
NxStage’s System One has received an expanded indication to treat patients overnight at home, which the company says improves quality of life.
You may also be interested in...
News Briefs: Teleflex Acquires Vidacare; Integra Buys Covidien’s DuraSeal Line
Teleflex buys Vidacare Corp. for $262.5 million. Integra LifeSciences acquires Covidien’s Confluent Surgical product line, including the DuraSeal products, for $235 million, plus up to $30 million in milestone payments. W.L. Gore ordered to pay more than $850 million to C.R. Bard to partially resolve a long-running patent dispute. More news.
Baxter Buys Gambro For $4 Billion To Round Out Dialysis Device Lineup
Deal builds on Baxter’s home peritoneal dialysis-focused business by adding a suite of products for hemodialysis in the clinic, including Gambro’s Artis and AK 96 systems.
FDA Guidance On Nocturnal Home Hemodialysis Outlines Clinical Trial Needs
An April 15 FDA guidance tells makers of nocturnal home hemodialysis systems what sorts of clinical trials they should perform to smooth the FDA pre-market clearance process